Compound: Pasireotide
SMILES: O=C1N2[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(N[C@H](C(N[C@H]1Cc3ccccc3)=O)Cc4ccc(OCc5ccccc5)cc4)=O)CCCCN)Cc6c7c(cccc7)[nH]c6)c8ccccc8)C[C@H](C2)OC(=O)NCCN
InChIKey: VMZMNAABQBOLAK-DBILLSOUSA-N
Synonyms: Pasireotide, 396091-73-9, SOM-230, SOM230, SOM 230, pasireotida, pasireotidum, CHEBI:72312, 98H1T17066, Cyclo((4R)-4-(2-aminoethylcarbamoyloxy)-L-prolyl-L-phenylglycyl-D-tryptophyl-L-lysyl-4-O-benzyl-L-tyrosyl-L-phenylalanyl-), cyclo[(2S)-2-phenylglycyl-D-tryptophyl-L-lysyl-O-benzyl-L-tyrosyl-L-phenylalanyl-(4R)-4-{[(2-aminoethyl)carbamoyl]oxy}-L-prolyl], DTXSID501026040, ((3S,6S,9S,12R,15S,18S,20R)-9-(4-aminobutyl)-12-(1H-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-15-phenyl-6-((4-(phenylmethoxy)phenyl)methyl)-3-(phenylmethyl)-1,4,7,10,13,16-hexazabicyclo(16.3.0)henicosan-20-yl) N-(2-aminoethyl)carbamate, [(3S,6S,9S,12R,15S,18S,20R)-9-(4-aminobutyl)-12-(1H-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-15-phenyl-6-[[4-(phenylmethoxy)phenyl]methyl]-3-(phenylmethyl)-1,4,7,10,13,16-hexazabicyclo[16.3.0]henicosan-20-yl] N-(2-aminoethyl)carbamate, cyclo((2S)-2-phenylglycyl-D-tryptophyl-L-lysyl-O-benzyl-L-tyrosyl-L-phenylalanyl-(4R)-4-(((2-aminoethyl)carbamoyl)oxy)-L-prolyl), RefChem:57495, H01CB05, DTXCID201510773, Pasireotide free base, Pasireotide [USAN:INN], UNII-98H1T17066, CHEMBL3349607, [(3S,6S,9S,12R,15S,18S,20R)-9-(4-aminobutyl)-3-benzyl-12-(1H-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-15-phenyl-6-[(4-phenylmethoxyphenyl)methyl]-1,4,7,10,13,16-hexazabicyclo[16.3.0]henicosan-20-yl] N-(2-aminoethyl)carbamate, MFCD08067735, (3S,6R,9S,12S,15S,19R,20aS)-6-((1H-indol-3-yl)methyl)-9-(4-aminobutyl)-15-benzyl-12-(4-(benzyloxy)benzyl)-1,4,7,10,13,16-hexaoxo-3-phenylicosahydropyrrolo[1,2-a][1,4,7,10,13,16]hexaazacyclooctadecin-19-yl (2-aminoethyl)carbamate, cyclo((4R)-4-(2-aminoethylcarbamoyloxy)-L-prolyl-L-phenylglycyl-D-tryptophyl-L-lysyl-4-O-benzyl-L-tyrosyl-L- phenylalanyl-), Pasireotide [INN], PASIREOTIDE [USAN], 396091-73-9 (free base), PASIREOTIDE [MI], PASIREOTIDE [VANDF], PASIREOTIDE [MART.], PASIREOTIDE [WHO-DD], GTPL2018, orb1992729, SCHEMBL12462108, SCHEMBL30472714, SOM 320, C58H66N10O9, BDBM50474236, EBC-27518, AKOS030526804, AT41874, DB06663, NCGC00378682-03, (3S,6R,9S,12S,15S,19R,20aS)-9-(4-aminobutyl)-15-benzyl-12-{[4-(benzyloxy)phenyl]methyl}-6-[(1H-indol-3-yl)methyl]-1,4,7,10,13,16-hexaoxo-3-phenyl-icosahydropyrrolo[1,2-a]1,4,7,10,13,16-hexaazacyclooctadecan-19-yl N-(2-aminoethyl)carbamate, AC-38391, FP110151, HY-16381, EN300-23849528, Q3896970, BRD-K59715032-362-01-4, Cyclo(-Hyp (2-aminoethyl-carbamoyl)-Phg-D-Trp-Lys-Tyr(Bzl)-Phe) acetate, [(3S,6S,9S,12R,15S,18S,20R)-9-(4-aminobutyl)-3-benzyl-6-[(4-benzyloxyphenyl)methyl]-12-(1H-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-15-phenyl-1,4,7,10,13,16-hexazabicyclo[16.3.0]henicosan-20-yl] N-(2-aminoethyl)carbamate, 1498076-00-8
Theoretical properties:
molecular_formula: C58H66N10O9
molecular_weight: 1047.2 g/mol
exact_mass: 1046.50142372 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 9
hydrogen_bond_acceptor_count: 11
rotatable_bond_count: 18
heavy_atom_count: 77
topological_polar_surface_area: 281 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
solubility: Soluble in water.
Descriptions:
{"pubchem": "Pasireotide is a six-membered homodetic cyclic peptide composed from L-phenylglycyl, D-tryptophyl, L-lysyl, O-benzyl-L-tyrosyl, L-phenylalanyl and modified L-hydroxyproline residues joined in sequence. A somatostatin analogue with pharmacologic properties mimicking those of the natural hormone somatostatin; used (as its diaspartate salt) for treatment of Cushing's disease. It has a role as an antineoplastic agent. It is a homodetic cyclic peptide and a peptide hormone. It is a conjugate base of a pasireotide(2+).", "chebi": "A six-membered homodetic cyclic peptide composed from <small>L</small>-phenylglycyl, <small>D</small>-tryptophyl, <small>L</small>-lysyl, <em>O</em>-benzyl-<small>L</small>-tyrosyl, <small>L</small>-phenylalanyl and modified <small>L</small>-hydroxyproline residues joined in sequence. A somatostatin analogue with pharmacologic properties mimicking those of the natural hormone somatostatin; used (as its diaspartate salt) for treatment of Cushing's disease.", "chembl": "PASIREOTIDE is a protein listed in the ChEMBL database and has reached clinical trial phase 4.0.", "wikipedia": "Pasireotide, sold under the brand name Signifor, is an orphan drug approved in the United States and the European Union for the treatment of Cushing's disease in patients who fail or are ineligible for surgical therapy. It was developed by Novartis. Pasireotide is a somatostatin analog with a 40-fold increased affinity to somatostatin receptor 5 compared to other somatostatin analogs.\nThe most common side effects include hyperglycaemia (high blood sugar levels), diabetes, diarrhoea, abdominal pain (stomach ache), nausea (feeling sick), cholelithiasis (gallstones), injection site reactions, and tiredness.\nPasireotide was approved for Cushing's disease by the European Medicines Agency (EMA) in April 2012  and by the U.S. Food and Drug Administration (FDA) in December 2012.\nPasireotide LAR (the long-acting-release formulation) was approved by the FDA for treatment of acromegaly in December 2014, and had been approved for this indication by the EMA in September 2014."}